Metastatic Prostate Cancers with BRCA2 versus ATM Mutations Exhibit Divergent Molecular Features and Clinical Outcomes.
Justin H HwangXiaolei ShiAndrew ElliottTaylor E ArnoffJulie E McGrathJoanne XiuPhillip WalkerHannah E BergomAbderrahman DayShihab AhmedSydney TapeAllison MakovecAtef AliRami M ShakerEamon ToyeRachel PassowJohn R LozadaJinhua WangEmil LouKent W MouwBenedito Arruda CarneiroElisabeth I HeathRana R McKayWolfgang Michael KornChadi NabhanCharles J RyanEmmanuel S AntonarakisPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2023)
Tumoral ATM and BRCA2 mutations are associated with differential clinical outcomes when patients are stratified by treatments including hormonal or taxanes therapies. ATM- and BRCA2-mutated tumors exhibited differences in co-occurring molecular features. These unique molecular features may inform therapeutic decisions and development of novel therapies.
Keyphrases
- dna damage
- dna repair
- end stage renal disease
- dna damage response
- prostate cancer
- squamous cell carcinoma
- ejection fraction
- newly diagnosed
- chronic kidney disease
- small cell lung cancer
- prognostic factors
- oxidative stress
- peritoneal dialysis
- type diabetes
- breast cancer risk
- patient reported outcomes
- metabolic syndrome
- benign prostatic hyperplasia
- insulin resistance